Get the Stockscreener App
31.27
0.13%
-0.04
Stoke Therapeutics Inc stock is traded at $31.27, with a volume of 495.12K.
It is down -0.13% in the last 24 hours and up +7.35% over the past month.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
See More
Previous Close:
$31.31
Open:
$31.7
24h Volume:
495.12K
Relative Volume:
0.63
Market Cap:
$2.02B
Revenue:
$32.08M
Net Income/Loss:
$-169.77M
P/E Ratio:
-11.00
EPS:
-2.8418
Net Cash Flow:
$-147.70M
1W Performance:
-4.40%
1M Performance:
+7.35%
6M Performance:
-2.01%
1Y Performance:
+82.12%
1-Day Range:
$30.20
$31.70
1-Week Range:
$30.20
$33.56
52-Week Range:
$16.90
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
31.27 | 2.13B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-05-26 | Initiated | Guggenheim | Buy |
| Jan-05-26 | Resumed | Chardan Capital Markets | Buy |
| Jul-18-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Mar-26-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Jul-25-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
Stoke Therapeutics (STOK) gets 6.5% stake disclosure from Lynx1 Capital - Stock Titan
Trading Systems Reacting to (STOK) Volatility - Stock Traders Daily
Stoke Therapeutics (STOK): TD Bank, TD Securities disclose 4.9% equity stake - Stock Titan
Stoke Therapeutics at canaccord growth conference: trial momentum builds By Investing.com - Investing.com Canada
Stoke Therapeutics at canaccord growth conference: trial momentum builds - Investing.com
Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript - The Globe and Mail
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - The National Law Review
Stoke Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:STOK) 2026-08-07 - Seeking Alpha
Stoke Therapeutics Inc (STOK) Stock News Today - tradingkey.com
Stoke Therapeutics, Inc. (STOK) Investor Outlook: A Promising 43.5% Upside In Biotech's Genetic Revolution - directorstalkinterviews.com
What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing? - Yahoo Finance
FMR LLC discloses 8.5% Stoke Therapeutics (STOK) ownership in Schedule 13G/A - Stock Titan
Analysts Have Made A Financial Statement On Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Second-Quarter Report - simplywall.st
Stoke Therapeutics Inc (STOK) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Stoke Therapeutics (STOK) CMO sells 7,176 shares under 10b5-1 plan - Stock Titan
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $40 to $60 - Moomoo
Stoke: 'Buy' Zorevunersen NDA SCN1A DS And STK-002 Advancement (NASDAQ:STOK) - Seeking Alpha
Stoke Therapeutics CMO Barry Ticho disposes of USD 208,707 in common shares - Bitget
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - marketscreener.com
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Stoke Therapeutics (STOK) - The Globe and Mail
STOK Maintained by Canaccord Genuity -- Price Target Lowered to $58 - GuruFocus
These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results - webull.com
STOK Maintains Rating by Wedbush -- Price Target Raised to $40 - GuruFocus
STOK Reiterated by Guggenheim -- Price Target Maintained at $60 - GuruFocus
Wedbush Adjusts Price Target on Stoke Therapeutics to $40 From $38, Maintains Outperform Rating - marketscreener.com
Stoke Therapeutics, Inc. Q2 2026 Earnings Call Summary - finance.yahoo.com
Canaccord lowers Stoke Therapeutics stock price target to $58 By Investing.com - Investing.com Canada
Stoke Therapeutics Is Maintained at Buy by Chardan Capital - Moomoo
Stoke Therapeutics, Inc. Stock 12‑Month Price Target Cut to $45.64, Implies 54% Upside - TradingView
STOK SWOT Analysis: Financial Strength and Overvaluation Concerns Revealed in 10-Q Filing - GuruFocus
Stoke Therapeutics Q2 Results: Sales beat estimates, EPS misses - scanx.trade
Stoke Therapeutics Inc (STOK) (Q2 2026) Earnings Call Highlights - GuruFocus
Earnings call transcript: Stoke Therapeutics posts Q2 2026 revenue beat as Dravet drug advances - Investing.com Nigeria
Stoke Therapeutics Q2 Earnings Call Highlights - Yahoo Finance
Transcript : Stoke Therapeutics, Inc., Q2 2026 Earnings Call, Aug 03, 2026 - marketscreener.com
Stoke Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Stoke Therapeutics Q2 Loss Widens, Revenue Falls - marketscreener.com
Stoke Therapeutics, Inc. Q2 2026: Revenue $9.3M, EPS $(0.93) — 10-Q Summary - TradingView
Stoke Therapeutics reports Q2 2026 net loss $61.6M, $420M cash runway; Phase 3 zorevunersen enrollment complete - TradingView
Earnings Flash (STOK) Stoke Therapeutics, Inc. Reports Q2 Revenue $9.3M, vs. FactSet Est of $4.9M - marketscreener.com
Stoke Therapeutics Q2 revenue falls 33% on lower collaboration, licensing income - TradingView
STOK: Phase 3 Dravet study enrollment complete; $420M cash funds operations through early 2028 - TradingView
Stoke Therapeutics (NASDAQ: STOK) swings to H1 2026 loss as revenue falls - Stock Titan
Stoke Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings - 24/7 Wall St.
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates - Yahoo Finance
Stoke Therapeutics faces earnings test as Dravet drug awaits data By Investing.com - Investing.com India
Stoke Therapeutics faces earnings test as Dravet drug awaits data - Investing.com
Stoke Therapeutics, Inc. (STOK) Investor Outlook: Navigating the 52.52% Potential Upside in Biotech - directorstalkinterviews.com
EcoR1 Capital LLC Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Inc (STOK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):